Search
Minnesota Paid Clinical Trials
A listing of 2098 clinical trials in Minnesota actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
661 - 672 of 2098
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Minnesota is currently home to 2098 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/20/2025
Locations: Minneapolis Clinic of Neurology - Burnsville Office, Burnsville, Minnesota
Conditions: Chronic Migraine
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
Recruiting
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Recruiting
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/20/2025
Locations: Mayo Clinic Health Systems - Austin, Austin, Minnesota
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota
Conditions: Mitral Valve Regurgitation
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hepatocellular Cancer
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Recruiting
The overall objectives of this BETRNet Research Center (RC) are:
1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA)
2. to increase the biological understanding of key observations made by our clinical researchers;
3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Barrett's Esophagus, Esophageal Neoplasm
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Recruiting
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME).
In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be ent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Edina, MN, Edina, Minnesota
Conditions: Diabetic Macular Edema (DME)
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
Recruiting
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 6 months affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in adults with failing Fontan circulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure with Preserved Ejection Fraction
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Minneapolis, MN, Minneapolis, Minnesota
Conditions: Diabetic Macular Edema (DME)
Avalus Ultra Post-Approval Study (PAS)
Recruiting
The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Aortic Valve Disease
RECOVER-ENERGIZE Platform Protocol
Recruiting
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Long COVID, Long Covid19, Long Covid-19